新型PSMA靶向[177Lu]Lu-P17-087与其白蛋白结合衍生物[177Lu]Lu-P17-088在转移性去势抵抗性前列腺癌患者中的比较:首次人体研究
本首次人体研究在转移性去势抵抗性前列腺癌(mCRPC)患者中比较了新型PSMA靶向放射性配体治疗药物[177Lu]Lu-P17-087(5例)与其白蛋白结合修饰衍生物[177Lu]Lu-P17-088(4例),每例给药1.2 GBq。主要终点为剂量学评估,次要终点为放射性毒性(CTCAE 5.0)和PSA反应(PCWG3)。[177Lu]Lu-P17-088因白蛋白结合致血液循环时间延长而表现出更高的有效剂量和更慢的清除,两种药物均显示良好的PSMA靶向剂量递送,作者认为二者是有前景的RLT药物,并指出需增加剂量和频次的进一步研究来评估潜在疗效。
要点
- [177Lu]Lu-P17-088的有效剂量高于[177Lu]Lu-P17-087(0.151 ± 0.036 vs. 0.056 ± 0.019 mGy/MBq,P = 0.001)。
- [177Lu]Lu-P17-087肿瘤平均剂量低于[177Lu]Lu-P17-088(4.72 ± 2.29 vs. 7.75 ± 4.18 mGy/MBq,P = 0.018)。
- 低剂量治疗下患者未出现主要临床副作用,[177Lu]Lu-P17-087组3/5例、[177Lu]Lu-P17-088组3/4例PSA值下降。
核心结论
- [177Lu]Lu-P17-088与[177Lu]Lu-P17-087药代动力学不同,但在mCRPC患者中均表现出良好的PSMA靶向剂量递送。
- 作者认为这两种药物是有前景的RLT药物,可用于mCRPC的个体化治疗。
- 作者指出需增加剂量和频次的进一步研究来评估潜在治疗效果。
研究设计与样本
- 首次人体研究,纳入经[68Ga]Ga-PSMA-11 PET/CT扫描证实PSMA阳性肿瘤的患者。
- 5例mCRPC患者接受[177Lu]Lu-P17-087,另4例患者接受[177Lu]Lu-P17-088,每例1.2 GBq。
- 注射后1.5、4、24、48、72、120和168小时行多次全身平面显像,注射后24小时行一次SPECT/CT显像。
- 主要终点为剂量学评估,次要终点为放射性毒性评估(CTCAE 5.0)和PSA反应(PCWG3)。
主要发现
- 在该低剂量治疗下患者未出现主要临床副作用。
- [177Lu]Lu-P17-088因白蛋白结合致血液循环时间延长,其有效剂量高于[177Lu]Lu-P17-087(0.151 ± 0.036 vs. 0.056 ± 0.019 mGy/MBq,P = 0.001)。
- 红骨髓剂量分别为0.119 ± 0.068和0.048 ± 0.020 mGy/MBq,肾脏剂量分别为0.119 ± 0.068和0.046 ± 0.022 mGy/MBq([177Lu]Lu-P17-088 vs. [177Lu]Lu-P17-087)。
- [177Lu]Lu-P17-087表现出优异的肿瘤摄取和更快的动力学,而[177Lu]Lu-P17-088清除更慢且平均肿瘤剂量更高(7.75 ± 4.18 vs. 4.72 ± 2.29 mGy/MBq,P = 0.018)。
- 给予[177Lu]Lu-P17-087和[177Lu]Lu-P17-088后,分别有3/5和3/4例患者PSA值下降。
关键数值与推荐
- [177Lu]Lu-P17-088组有效剂量0.151 ± 0.036 mGy/MBq vs. [177Lu]Lu-P17-087组0.056 ± 0.019 mGy/MBq,P = 0.001。
- [177Lu]Lu-P17-088组红骨髓剂量0.119 ± 0.068 mGy/MBq vs. [177Lu]Lu-P17-087组0.048 ± 0.020 mGy/MBq;肾脏剂量分别为0.119 ± 0.068 vs. 0.046 ± 0.022 mGy/MBq。
- [177Lu]Lu-P17-088组平均肿瘤剂量7.75 ± 4.18 mGy/MBq vs. [177Lu]Lu-P17-087组4.72 ± 2.29 mGy/MBq,P = 0.018。
- 放射性毒性按CTCAE 5.0评估,PSA反应按PCWG3评估。
临床怎么用
- 原文结论指出这两种药物是有前景的RLT药物,可用于mCRPC的个体化治疗,并指出需增加剂量和频次的进一步研究来评估潜在治疗效果。
局限性
- 原文结论指出需增加剂量和频次的进一步研究来评估潜在治疗效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific membrane antigen (PSMA) is a promising target for diagnosis and radioligand therapy (RLT) of prostate cancer. Two novel PSMA-targeting radionuclide therapy agents, [177Lu]Lu-P17-087, and its albumin binder modified derivative, [177Lu]Lu-P17-088, were evaluated in metastatic castration-resistant prostate cancer (mCRPC) patients. The primary endpoint was dosimetry evaluation, the second endpoint was radiation toxicity assessment (CTCAE 5.0) and PSA response (PCWG3). METHODS: Patients with PSMA-positive tumors were enrolled after [68Ga]Ga-PSMA-11 PET/CT scan. Five mCRPC patients received [177Lu]Lu-P17-087 and four other patients received [177Lu]Lu-P17-088 (1.2 GBq/patient). Multiple whole body planar scintigraphy was performed at 1.5, 4, 24, 48, 72, 120 and 168 h after injection and one SPECT/CT imaging was performed at 24 h post-injection for each patient. Dosimetry evaluation was compared in both patient groups. RESULTS: Patients showed no major clinical side-effects under this low dose treatment. As expected [177Lu]Lu-P17-088 with longer blood circulation (due to its albumin binding) exhibited higher effective doses than [177Lu]Lu-P17-087 (0.151 ± 0.036 vs. 0.056 ± 0.019 mGy/MBq, P = 0.001). Similarly, red marrow received 0.119 ± 0.068 and 0.048 ± 0.020 mGy/MBq, while kidney doses were 0.119 ± 0.068 and 0.046 ± 0.022 mGy/MBq, respectively. [177Lu]Lu-P17-087 demonstrated excellent tumor uptake and faster kinetics; while [177Lu]Lu-P17-088 displayed a slower washout and higher average dose (7.75 ± 4.18 vs. 4.72 ± 2.29 mGy/MBq, P = 0.018). After administration of [177Lu]Lu-P17-087 and [177Lu]Lu-P17-088, 3/5 and 3/4 patients showed reducing PSA values, respectively. CONCLUSION: [177Lu]Lu-P17-088 and [177Lu]Lu-P17-087 displayed different pharmacokinetics but excellent PSMA-targeting dose delivery in mCRPC patients. These two agents are promising RLT agents for personalized treatment of mCRPC. Further studies with increased dose and frequency of RLT are warranted to evaluate the potential therapeutic efficacy. TRIAL REGISTRATION: 177Lu-P17-087/177Lu-P17-088 in Patients with Metastatic Castration-resistant Prostate Cancer (NCT05603559, Registered at 25 October, 2022). URL OF REGISTRY: https://classic. CLINICALTRIALS: gov/ct2/show/NCT05603559 .
引用
- Li L, Wang J, Wang G, et al. Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study. Eur J Nucl Med Mol Imaging. 2024. PMID: 38658392. doi:10.1007/s00259-024-06721-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。